Rapt Therapeutics Inc (RAPT) Stock Price, Quote & News

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology

Sector: Healthcare

Phone: 650-489-9000

Website: www.rapt.com

Address:

561 Eccles Avenue, South San Francisco, United States

YouTubeYield Dec. 24 at 10:32 AM

$RAPT The next phase will be defined by how external catalysts materialize before balance-sheet pressure intensifies. Sustained traction would support a meaningful re-rating.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 1:06 PM

$RAPT RSI: 62.44, MACD: 1.3794 Vol: 2.04, MA20: 33.74, MA50: 30.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

dogDazeSummer Dec. 18 at 8:56 PM

$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX

1 · Reply

Quantumup Dec. 18 at 1:45 PM

TD Cowen🏁 $RAPT at a Buy rating. $RHHBY - $NVS $DBVT $AZN Here's what TD Cowen said in its initiation report: RAPT's ozureprubart (IgE mAb) is an improved version of Xolair for food allergy and CSU with less frequent dosing & broader efficacy. Chinese Ph2 CSU data confirm comparable/better efficacy vs Xolair with 16-wk durability, teeing up for potential global Ph3 start by YE26. Ph2b PrestlgE food allergy trial ongoing with data in H1:27. With validated MoA and multi-blockbuster potential, initiate Buy.

0 · Reply

JarvisFlow Dec. 18 at 1:07 PM

TD Cowen has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Buy.

0 · Reply

Breqqswings Dec. 9 at 4:45 PM

$RAPT

0 · Reply

SuperGreenToday Dec. 3 at 7:26 PM

$RAPT Share Price: $32.14 Contract Selected: May 15, 2026 $30 Calls Buy Zone: $6.38 – $7.88 Target Zone: $10.96 – $13.40 Potential Upside: 62% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Chevelle_SS Nov. 26 at 6:52 PM

$RAPT Let's get her back to $50 where she belongs!!

0 · Reply

Doozio Nov. 26 at 5:25 PM

$OLMA god these biotech $STOK s are causing a $RCUS after da 🐑 been shook it’s a $RAPP for da $RAPT or!

0 · Reply

BEATOFtheMARKET Nov. 23 at 4:03 PM

$RACE $RANI 🔥 $RAPP $RAPT $RBC

0 · Reply

RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Oct 27, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

Oct 21, 2025, 11:12 PM EDT - 2 months ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Oct 21, 2025, 4:01 PM EDT - 2 months ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Oct 20, 2025, 5:05 PM EDT - 2 months ago

RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

Oct 20, 2025, 9:42 AM EDT - 2 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RANI

Oct 20, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Oct 19, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

Sep 29, 2025, 5:00 AM EDT - 3 months ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Aug 7, 2025, 8:00 AM EDT - 5 months ago

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 8:00 AM EDT - 6 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 6 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Jun 4, 2025, 4:05 PM EDT - 7 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

May 8, 2025, 8:00 AM EDT - 8 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:00 AM EDT - 9 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Mar 6, 2025, 8:00 AM EST - 10 months ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 9, 2025, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Dec 23, 2024, 7:10 AM EST - 1 year ago

RAPT Therapeutics Announces $150 Million Private Placement

Nov 11, 2024, 10:34 AM EST - 1 year ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX SAGE TMCI LNAI

May 20, 2024, 4:35 AM EDT - 1 year ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 9, 2024, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Apr 9, 2024, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

Mar 7, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:30 PM EST - 1 year ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Feb 26, 2024, 4:00 AM EST - 1 year ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 20, 2024, 8:36 AM EST - 2 years ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 7:41 AM EST - 2 years ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:30 AM EST - 2 years ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 13, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Jan 31, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 2, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 27, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 13, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Nov 1, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Oct 18, 2023, 9:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Aug 30, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 7, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

YouTubeYield Dec. 24 at 10:32 AM

$RAPT The next phase will be defined by how external catalysts materialize before balance-sheet pressure intensifies. Sustained traction would support a meaningful re-rating.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 1:06 PM

0 · Reply

dogDazeSummer Dec. 18 at 8:56 PM

1 · Reply

Quantumup Dec. 18 at 1:45 PM

0 · Reply

JarvisFlow Dec. 18 at 1:07 PM

TD Cowen has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Buy.

0 · Reply

Breqqswings Dec. 9 at 4:45 PM

$RAPT

0 · Reply

SuperGreenToday Dec. 3 at 7:26 PM

0 · Reply

Chevelle_SS Nov. 26 at 6:52 PM

$RAPT Let's get her back to $50 where she belongs!!

0 · Reply

Doozio Nov. 26 at 5:25 PM

$OLMA god these biotech $STOK s are causing a $RCUS after da 🐑 been shook it’s a $RAPP for da $RAPT or!

0 · Reply

BEATOFtheMARKET Nov. 23 at 4:03 PM

$RACE $RANI 🔥 $RAPP $RAPT $RBC

0 · Reply

JarvisFlow Nov. 12 at 4:45 PM

JP Morgan has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Overweight with a target price of 55 → 57.

0 · Reply

JarvisFlow Nov. 7 at 3:49 PM

Barclays updates rating for RAPT Therapeutics ( $RAPT ) to Overweight, target set at 58 → 56.

0 · Reply

d_risk Nov. 6 at 4:44 PM

$RAPT - RAPT Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors RAPT’s 10-Q risk factors for 2025 reflect expanded disclosures on clinical, regulatory, and international risks; new details on IP, financing, and operational vulnerabilities; added risks from price controls, disaster recovery, product liability, data security, and analyst coverage; and highlight evolving partnerships, trial progress, and financial pressures—while consolidating and streamlining prior risk headings. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/RAPT/10-Q/2025-11-06

0 · Reply

anachartanalyst Nov. 3 at 7:02 PM

$RAPT https://anachart.com/wp-content/uploads/ana_temp/1762196544_soc-img.jpg

0 · Reply

IN0V8 Nov. 3 at 3:44 PM

$RAPT Buy Wells Fargo raises target price to $72 from $48

0 · Reply

JarvisFlow Nov. 3 at 2:10 PM

Wells Fargo has updated their rating for RAPT Therapeutics ( $RAPT ) to Overweight with a price target of 72.

0 · Reply

Tjcmd Nov. 2 at 5:26 PM

$RAPT Being touted as a superior product than Roche’s monoclonal AB Xolair: 1. Half- life 2x Xolair = less frequent dosing (especially important in kids) 2. No exclusions based on body weight or high IgE levels

0 · Reply

DARKP00L Oct. 27 at 5:14 PM

$RAPT 12:57 on Oct. 27 2025 HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72 #tradeideas

0 · Reply

notreload_ai Oct. 27 at 4:58 PM

Guggenheim started coverage of $RAPT with a Buy rating and $70 price target, citing the potential of its long-acting anti-IgE antibody in the growing food allergy market and comparing it to Roche’s Xolair.

0 · Reply

Quantumup Oct. 27 at 10:59 AM

Guggenheim🏁 $RAPT Buy/$70 $RHHBY $REGN - SNY $LLY $ABBV Guggenheim said: We are initiating coverage of RAPT Therapeutics, Inc. (RAPT) with a BUY rating and a price target of $70. Guggenheim went on to say:

0 · Reply

victor32 Oct. 23 at 7:46 PM

$RAPT "Hopefully, following the close of today’s offering, we’ll begin to see some upward movement."

0 · Reply

Market Cap	980.97M
Revenue (ttm)	0.00
Net Income (ttm)	-129.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	236,300
Avg Vol	557,092
Day's Range	N/A - N/A
Shares Out	27.71M
Stochastic %K	61%
Beta	0.43
Analysts	Strong Sell
Price Target	$65.00